Lu Yi, Zhang Wei, Fan Shujun, Liang Zhen, Li Zhongjia, Tian Jia, Kang Jiaqi, Song Yuxuan, Liu Kang, Zhou Kechong, Wang Xiao, Yang Yongjiao, Liu Xiaoqiang
Department of Urology, Tianjin Medical University General Hospital, Tianjin, China.
Division of Epidemiology, School of Medicine, University of California, Riverside, CA, United States.
Front Oncol. 2021 Jan 21;10:613366. doi: 10.3389/fonc.2020.613366. eCollection 2020.
Metabolic syndrome (MetS) and its components are associated with increased risks of several cancers. However, the relationship between MetS and upper tract urothelial carcinoma (UTUC) has never been investigated before.
We identified 3,785 UTUC cases aged over 65 years old within the Surveillance, Epidemiology and End Results-Medicare database between 2007 and 2016. For comparison, non-cancer controls (n = 189,953) were selected from the 5% random sample of individuals residing within regions of SEER registries and matched with cases through diagnosis date and pseudo-diagnosis date. MetS and its components were all defined by using ICD-9-CM codes. Multivariate logistic regression models were conducted to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Time trends for MetS and its components were reported and we also performed dose-response effect analysis to test the concomitant effect of these components. The study was presented following the STROBE reporting checklist.
UTUC risk was associated with metabolic syndrome (NCEP-III: OR: 1.669, 95% CI: 1.550-1.792; IDF: OR: 1.924, 95% CI: 1.676-2.172) and its component factors: elevated waist circumference/central adiposity (OR: 1.872, 95% CI: 1.693-2.055), impaired fasting glucose (OR: 1.306, 95% CI: 1.133-1.480), high blood pressure (OR: 1.295, 95% CI: 1.239-1.353), high triglycerides (OR: 1.280, 95% CI: 1.222-1.341), and low high-density lipoprotein cholesterol (OR: 1.354, 95% CI: 1.118-1.592). Consistent associations could also be observed in the subgroup analyses by tumor stages, grades, and tumor size. Additionally, the rates of MetS increased over time in both UTUC and control cohort (NCEP-III criterion; EAPC: +18.1%, 0.001; EAPC: +16.1%, 0.001, respectively). A significantly gradual increase in UTUC rates could be seen as the No. of the MetS components increase (² = 37.239, = 0.000).
Among people aged over 65, MetS and its components were significant risk factors for UTUC with consistent associations in different tumor stages, grades, and tumor size. Even if a subject who did not meet the criteria for MetS had only one of the components, he (she) still had an elevated risk for UTUC. Strategies to control the epidemic of MetS and its components might contribute to a reduction in the UTUC burden. The findings should be considered tentative until ascertained by more researches.
代谢综合征(MetS)及其组分与多种癌症风险增加相关。然而,此前从未研究过MetS与上尿路尿路上皮癌(UTUC)之间的关系。
我们在2007年至2016年的监测、流行病学和最终结果 - 医疗保险数据库中确定了3785例65岁以上的UTUC病例。为作比较,从监测、流行病学和最终结果(SEER)登记处所在地区的5%随机样本个体中选取非癌症对照(n = 189,953),并通过诊断日期和伪诊断日期与病例进行匹配。MetS及其组分均使用国际疾病分类第九版临床修正本(ICD - 9 - CM)编码定义。进行多变量逻辑回归模型以计算比值比(OR)和95%置信区间(CI)。报告了MetS及其组分的时间趋势,并且我们还进行了剂量反应效应分析以检验这些组分的伴随效应。本研究按照加强流行病学观察性研究报告规范(STROBE)报告清单进行展示。
UTUC风险与代谢综合征(美国国家胆固醇教育计划成人治疗组第三次报告标准(NCEP - III):OR:1.669,95% CI:1.550 - 1.792;国际糖尿病联盟标准(IDF):OR:1.924,95% CI:1.676 - 2.172)及其组分因素相关:腰围增加/中心性肥胖(OR:1.872,95% CI:1.693 - 2.055)、空腹血糖受损(OR:1.306,95% CI:1.133 - 1.480)、高血压(OR:1.295,95% CI:1.239 - 1.353)、高甘油三酯(OR:1.280,95% CI:1.222 - 1.341)以及低高密度脂蛋白胆固醇(OR:1.354,95% CI:1.118 - 1.592)。在按肿瘤分期、分级和肿瘤大小进行的亚组分析中也可观察到一致的关联。此外,UTUC和对照队列中MetS的发生率均随时间增加(NCEP - III标准;EAPC:+18.1%,P < 0.001;EAPC:+16.1%,P < 0.001)。随着MetS组分数量增加,UTUC发生率呈显著逐渐上升趋势(χ² = 37.239,P = 0.000)。
在65岁以上人群中,MetS及其组分是UTUC的重要危险因素,在不同肿瘤分期、分级和肿瘤大小中存在一致的关联。即使未达到MetS标准的个体仅有一种组分,其UTUC风险仍会升高。控制MetS及其组分流行的策略可能有助于减轻UTUC负担。在更多研究确定之前,这些发现应视为初步结论。